CA2922375C - Formes de sels d'alpha-tea: compositions et utilisations therapeutiques - Google Patents

Formes de sels d'alpha-tea: compositions et utilisations therapeutiques Download PDF

Info

Publication number
CA2922375C
CA2922375C CA2922375A CA2922375A CA2922375C CA 2922375 C CA2922375 C CA 2922375C CA 2922375 A CA2922375 A CA 2922375A CA 2922375 A CA2922375 A CA 2922375A CA 2922375 C CA2922375 C CA 2922375C
Authority
CA
Canada
Prior art keywords
compositions
alpha
salt forms
treating disease
tea salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2922375A
Other languages
English (en)
Other versions
CA2922375A1 (fr
Inventor
Michael O'neill
Barbara KIDON
Thomas Adkins
Hongqiao Wu
Emmanuel T. Akporiaye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of CA2922375A1 publication Critical patent/CA2922375A1/fr
Application granted granted Critical
Publication of CA2922375C publication Critical patent/CA2922375C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des sels du composé (I), des formes polymorphiques de ceux-ci, des procédés de préparation et d'utilisation de ceux-ci ainsi que des compositions pharmaceutiques de ces sels.
CA2922375A 2013-09-06 2014-09-05 Formes de sels d'alpha-tea: compositions et utilisations therapeutiques Active CA2922375C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874823P 2013-09-06 2013-09-06
US61/874,823 2013-09-06
PCT/US2014/054354 WO2015035212A1 (fr) 2013-09-06 2014-09-05 Formes de sels d'alpha-tea : compositions et utilisations thérapeutiques

Publications (2)

Publication Number Publication Date
CA2922375A1 CA2922375A1 (fr) 2015-03-12
CA2922375C true CA2922375C (fr) 2021-06-15

Family

ID=51570908

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2922375A Active CA2922375C (fr) 2013-09-06 2014-09-05 Formes de sels d'alpha-tea: compositions et utilisations therapeutiques

Country Status (9)

Country Link
US (2) US10370350B2 (fr)
EP (1) EP3041831B1 (fr)
JP (2) JP6675985B2 (fr)
AU (1) AU2014318014C1 (fr)
CA (1) CA2922375C (fr)
DK (1) DK3041831T3 (fr)
ES (1) ES2766324T3 (fr)
PL (1) PL3041831T3 (fr)
WO (1) WO2015035212A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041831B1 (fr) 2013-09-06 2019-10-23 Research Development Foundation Formes de sels d'alpha-tea : compositions et utilisations thérapeutiques
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
CN107050432B (zh) * 2017-02-28 2019-09-10 上海交通大学医学院 胃泌素在制备诊断和治疗乳腺癌药物中的应用
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
EP3646873A1 (fr) * 2018-10-31 2020-05-06 Aprofol AG Sels de folate
CN111635390A (zh) * 2020-06-30 2020-09-08 江南大学 一种低泡型α-生育酚表面活性剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4629734Y1 (fr) 1968-04-23 1971-10-14
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
JP2634047B2 (ja) * 1985-10-15 1997-07-23 ザ リポソ−ム カンパニ−，インコ−ポレイテツド アルファトコフェロールをベースとした小胞体
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
JP2002526446A (ja) * 1998-09-23 2002-08-20 リサーチ ディベロップメント ファンデーション トロフェロール、トコトリエノール、その他のクロマン及び側鎖誘導体、並びにそれらの利用
US6770672B1 (en) 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
KR100847678B1 (ko) * 2000-02-11 2008-07-23 리서치 디벨럽먼트 파운데이션 토코페롤, 토코트리에놀, 다른 크로만 및 측쇄 유도체, 및이들의 용도
EP1463487B1 (fr) * 2001-12-19 2010-05-19 Research Development Foundation Administration de preparations liposomales de composes a base de vitamine e
EP3041831B1 (fr) 2013-09-06 2019-10-23 Research Development Foundation Formes de sels d'alpha-tea : compositions et utilisations thérapeutiques

Also Published As

Publication number Publication date
JP6675985B2 (ja) 2020-04-08
EP3041831B1 (fr) 2019-10-23
ES2766324T3 (es) 2020-06-12
JP2016532714A (ja) 2016-10-20
DK3041831T3 (da) 2020-01-27
JP2020063294A (ja) 2020-04-23
PL3041831T3 (pl) 2021-07-19
US20160214954A1 (en) 2016-07-28
US20200148661A1 (en) 2020-05-14
AU2014318014C1 (en) 2018-11-15
US10370350B2 (en) 2019-08-06
AU2014318014A1 (en) 2016-03-17
CA2922375A1 (fr) 2015-03-12
US10934267B2 (en) 2021-03-02
EP3041831A1 (fr) 2016-07-13
WO2015035212A1 (fr) 2015-03-12
AU2014318014B2 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
WO2017100726A8 (fr) Méthodes de traitement de la maladie de huntington
CA2894892A1 (fr) Derives d'acide boronique et leurs utilisations therapeutiques
PH12016500169A1 (en) Polymorph of syk inhibitors
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
CA2894891A1 (fr) Derives d'acide boronique et leurs utilisations therapeutiques
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
PH12016501122B1 (en) Delayed release compositions of linaclotide
CA2929436C (fr) Composes, composition pharmaceutique et methodes a utiliser dans le traitement de maladies inflammatoires
EA201600434A1 (ru) Применение производных бензимидазолпролина
UA115357C2 (uk) Похідні піридин-4-ілу
CA2899024C (fr) Formes cristallines d'acide {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetique
CA2922375C (fr) Formes de sels d'alpha-tea: compositions et utilisations therapeutiques
HK1217295A1 (zh) 4'-疊氮基，3'-脫氧基-3'-氟取代的核苷衍生物
WO2014035846A3 (fr) Composés azaindole substitué, leurs sels, leurs compositions pharmaceutiques et leurs procédés d'utilisation
WO2015068175A3 (fr) Procédé perfectionné de préparation de pazopanib ou d'un sel de qualité pharmaceutique de celui-ci
WO2015052568A3 (fr) Formes solides de curcumine et de dérivés de curcumine
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2015002755A3 (fr) Composés pour le traitement du paludisme
HK1212978A1 (zh) 芥子酸的新型衍生物
WO2017064558A8 (fr) Nouveau immunostimulant
WO2016014864A8 (fr) Hydroxy-(r)-2,2'-bisméthylnaltrexones et leurs utilisations
EA201690908A1 (ru) Пиразолопиримидиновые соединения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190821

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240904

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240904

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240904

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260416